Pathological brain ageing: Evaluation of the efficacy of a pharmacological aid

C. Guarnaschelli, G. Fugazza, C. Pistarini

Research output: Contribution to journalArticle

Abstract

The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.

Original languageEnglish
Pages (from-to)715-718
Number of pages4
JournalDrugs under Experimental and Clinical Research
Volume14
Issue number11
Publication statusPublished - 1988

Fingerprint

Motor Activity
Pharmacology
Acetylcarnitine
Aptitude
Brain
Neurotransmitter Agents
Rehabilitation
Quality of Life
Depression
Membranes
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Drug Discovery
  • Pharmacology

Cite this

Pathological brain ageing : Evaluation of the efficacy of a pharmacological aid. / Guarnaschelli, C.; Fugazza, G.; Pistarini, C.

In: Drugs under Experimental and Clinical Research, Vol. 14, No. 11, 1988, p. 715-718.

Research output: Contribution to journalArticle

@article{79774ff622154cbc8ec4e27e0f76fd65,
title = "Pathological brain ageing: Evaluation of the efficacy of a pharmacological aid",
abstract = "The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.",
author = "C. Guarnaschelli and G. Fugazza and C. Pistarini",
year = "1988",
language = "English",
volume = "14",
pages = "715--718",
journal = "Drugs under Experimental and Clinical Research",
issn = "0378-6501",
publisher = "Bioscience Ediprint Inc.",
number = "11",

}

TY - JOUR

T1 - Pathological brain ageing

T2 - Evaluation of the efficacy of a pharmacological aid

AU - Guarnaschelli, C.

AU - Fugazza, G.

AU - Pistarini, C.

PY - 1988

Y1 - 1988

N2 - The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.

AB - The efficacy of a molecule active at metabolic, neurotransmitter and membrane levels was evaluated in a group of 20 patients with typical involutional symptoms, who came under the care of the rehabilitation therapist for their concomitant decrease of motor activities. All subjects were treated with 1.5 g/day L-acetylcarnitine per os for 6 months, and subjected to the evaluation of cognitive ability (MMS), depression (HDRS), and behavioral and self-sufficiency performances (SCAG), at baseline (t0), after 90 days (t1), and after 180 days (t2). Whereas the basal evaluation showed disorders at all levels, the treatment gave a statistically significant improvement of all performances at both t1 and t2, achieving an effective recovery of the patients' quality of life, an improved participation in family and social life, and a diminished inertness in motor activity, which was the reason why they were studied.

UR - http://www.scopus.com/inward/record.url?scp=0024215918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024215918&partnerID=8YFLogxK

M3 - Article

C2 - 3246216

AN - SCOPUS:0024215918

VL - 14

SP - 715

EP - 718

JO - Drugs under Experimental and Clinical Research

JF - Drugs under Experimental and Clinical Research

SN - 0378-6501

IS - 11

ER -